RONALD H YANAGIHARA
- Type
- Physician · Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology
- Where
- GILROY, CA
- NPI
- 1366478240
- Received
- $14,494 in 55 records, 2019 to 2025
- As principal investigator
- $99,418 of research payments to others in 41 records
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 5 | $365 |
| 2024 | General payment | 2 | $123 |
| 2023 | General payment | 6 | $111 |
| 2022 | General payment | 2 | $324 |
| 2021 | General payment | 17 | $6,125 |
| 2020 | General payment | 17 | $3,602 |
| 2019 | General payment | 6 | $3,841 |
By company
| Company | Records | Amount | Years |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $6,246 | 2019–2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $2,147 | 2020 |
| G1 Therapeutics, Inc. | 1 | $1,500 | 2021 |
| Blueprint Medicines Corporation | 2 | $1,437 | 2020–2021 |
| BeiGene, Ltd. | 1 | $1,350 | 2021 |
| EMD Serono, Inc. | 1 | $500 | 2021 |
| PFIZER INC. | 22 | $354 | 2019–2021 |
| Merck Sharp & Dohme LLC | 2 | $202 | 2019 |
| Novocure GmbH | 1 | $200 | 2022 |
| Janssen Biotech, Inc. | 3 | $189 | 2021–2025 |
| Janssen Scientific Affairs, LLC | 1 | $102 | 2025 |
| Exelixis Inc. | 3 | $100 | 2019–2023 |
| Daiichi Sankyo Inc. | 1 | $73 | 2025 |
| Novartis Pharmaceuticals Corporation | 1 | $24 | 2023 |
| Astellas Pharma US Inc | 1 | $24 | 2023 |
| Eisai Inc. | 1 | $18 | 2023 |
| Gilead Sciences, Inc. | 1 | $11 | 2021 |
| Janssen Pharmaceuticals, Inc | 1 | $11 | 2020 |
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Consulting Fee | 6 | $9,810 |
| Honoraria | 3 | $3,006 |
| Food and Beverage | 20 | $1,279 |
| Education | 26 | $399 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-16 | Janssen Biotech, Inc. | $146 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2025-12-05 | Daiichi Sankyo Inc. | $73 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-20 | Janssen Biotech, Inc. | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-11-12 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | LYNPARZA Drug, Oncology | 2025 | |
| 2025-09-25 | Janssen Scientific Affairs, LLC | $102 | Food and Beverage | In-kind items and services | RYBREVANT Drug, Oncology | 2025 | |
| 2024-11-05 | AstraZeneca Pharmaceuticals LP | $17 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2024 | |
| 2024-06-17 | AstraZeneca Pharmaceuticals LP | $106 | Food and Beverage | In-kind items and services | 2024 | ||
| 2023-09-27 | AstraZeneca Pharmaceuticals LP | $15 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2023 | |
| 2023-08-21 | Eisai Inc. | $18 | Food and Beverage | Cash or cash equivalent | Lenvima Drug, Oncology | 2023 | |
| 2023-07-06 | Novartis Pharmaceuticals Corporation | $24 | Food and Beverage | In-kind items and services | LUTATHERA Drug, Oncology | 2023 | |
| 2023-06-29 | AstraZeneca Pharmaceuticals LP | $12 | Food and Beverage | In-kind items and services | ENHERTU Biological, Oncology | 2023 | |
| 2023-05-16 | Exelixis Inc. | $15 | Food and Beverage | Cash or cash equivalent | CABOMETYX Drug, Oncology | 2023 | |
| 2023-03-07 | Astellas Pharma US Inc | $24 | Food and Beverage | In-kind items and services | Xtandi Drug, Oncology | 2023 | |
| 2022-02-01 | AstraZeneca Pharmaceuticals LP | $124 | Food and Beverage | In-kind items and services | IMFINZI Biological, Oncology | 2022 | |
| 2022-01-19 | Novocure GmbH | $200 | Honoraria | Cash or cash equivalent | 2022 | ||
| 2021-11-16 | PFIZER INC. | $7 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-10-31 | AstraZeneca Pharmaceuticals LP | $2,397 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-09-29 | PFIZER INC. | $8 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-09-28 | PFIZER INC. | $12 | Education | In-kind items and services | IBRANCE Drug, ONCOLOGY | 2021 | |
| 2021-09-15 | Janssen Biotech, Inc. | $17 | Food and Beverage | In-kind items and services | 2021 | ||
| 2021-08-20 | G1 Therapeutics, Inc. | $1,500 | Honoraria | Cash or cash equivalent | COSELA Drug, ONCOLOGY | 2021 | |
| 2021-07-12 | Blueprint Medicines Corporation | $130 | Food and Beverage | In-kind items and services | GAVRETO Drug, Oncology / Rare Diseases | 2021 | |
| 2021-07-05 | BeiGene, Ltd. | $1,350 | Consulting Fee | Cash or cash equivalent | 2021 | ||
| 2021-06-22 | EMD Serono, Inc. | $500 | Consulting Fee | Cash or cash equivalent | Tepmetko Drug, Oncology | 2021 | |
| 2021-06-01 | Gilead Sciences, Inc. | $11 | Education | In-kind items and services | 2021 | ||
| 2021-04-15 | PFIZER INC. | $124 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-04-15 | PFIZER INC. | $8 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-04-13 | PFIZER INC. | $13 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-04-13 | PFIZER INC. | $8 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-03-24 | PFIZER INC. | $13 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-01-13 | PFIZER INC. | $13 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2021-01-13 | PFIZER INC. | $8 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2021 | |
| 2020-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,068 | Consulting Fee | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | 2020 | |
| 2020-12-08 | Takeda Pharmaceuticals U.S.A., Inc. | $1,068 | Consulting Fee | Cash or cash equivalent | ALUNBRIG Drug, ONCOLOGY | 2020 | |
| 2020-11-05 | PFIZER INC. | $11 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-11-05 | PFIZER INC. | $8 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-10-15 | Takeda Pharmaceuticals U.S.A., Inc. | $9 | Education | In-kind items and services | 2020 | ||
| 2020-10-08 | PFIZER INC. | $13 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2020 | |
| 2020-09-09 | Blueprint Medicines Corporation | $1,306 | Honoraria | Cash or cash equivalent | 2020 | ||
| 2020-08-19 | PFIZER INC. | $13 | Education | In-kind items and services | INLYTA Drug, ONCOLOGY | 2020 | |
| 2020-02-19 | Janssen Pharmaceuticals, Inc | $11 | Education | In-kind items and services | ERLEADA Drug, Oncology | 2020 | |
| 2020-02-13 | PFIZER INC. | $13 | Education | In-kind items and services | XALKORI Drug, ONCOLOGY | 2020 | |
| 2020-02-13 | PFIZER INC. | $13 | Education | In-kind items and services | BRAFTOVI Drug, ONCOLOGY | 2020 | |
| 2020-02-13 | PFIZER INC. | $11 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-02-13 | PFIZER INC. | $8 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-02-10 | PFIZER INC. | $13 | Education | In-kind items and services | XALKORI Drug, ONCOLOGY | 2020 | |
| 2020-02-10 | PFIZER INC. | $11 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-02-10 | PFIZER INC. | $8 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2020 | |
| 2020-01-15 | Exelixis Inc. | $11 | Education | In-kind items and services | Cabometyx Drug, Oncology | 2020 | |
| 2019-11-18 | PFIZER INC. | $11 | Education | In-kind items and services | LORBRENA Drug, ONCOLOGY | 2019 | |
| 2019-07-12 | Merck Sharp & Dohme LLC | $124 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-03-10 | AstraZeneca Pharmaceuticals LP | $3,425 | Consulting Fee | Cash or cash equivalent | TAGRISSO Drug, Oncology | 2019 | |
| 2019-02-01 | AstraZeneca Pharmaceuticals LP | $129 | Food and Beverage | In-kind items and services | 2019 | ||
| 2019-02-01 | Merck Sharp & Dohme LLC | $78 | Food and Beverage | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | 2019 | |
| 2019-01-31 | Exelixis Inc. | $73 | Food and Beverage | In-kind items and services | Cabometyx Drug, Oncology | 2019 |
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2022-04-13 | Takeda Pharmaceuticals U.S.A., Inc. | HAWAII PACIFIC HEALTH | $3,000 | A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLAT | 2022 |
| 2022-04-13 | Takeda Pharmaceuticals U.S.A., Inc. | HAWAII PACIFIC HEALTH | $12,000 | A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLAT | 2022 |
| 2021-11-24 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $2,850 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-11-09 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $1,745 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-11-04 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $100 | 2021 | |
| 2021-11-04 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $850 | 2021 | |
| 2021-10-01 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $490 | 2021 | |
| 2021-09-23 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $300 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-09-20 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $2,009 | 2021 | |
| 2021-09-07 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $2,641 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-07-29 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $2,641 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-07-29 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $150 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-07-29 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $200 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-07-20 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $1,220 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-07-20 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $490 | 2021 | |
| 2021-07-01 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $2,009 | 2021 | |
| 2021-06-30 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $5,283 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-06-23 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $100 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-06-22 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $2,441 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-06-11 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $431 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-06-03 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $9,158 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-05-20 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $250 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-04-30 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $3,962 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-04-26 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $150 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-03-30 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $4,235 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-03-04 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $50 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-03-02 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $4,160 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-02-24 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $1,875 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-02-17 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $597 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-01-25 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $490 | 2021 | |
| 2021-01-07 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $475 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-01-07 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $597 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-01-07 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $3,923 | Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c- | 2021 |
| 2021-01-06 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $2,100 | 2021 | |
| 2021-01-06 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $2,233 | 2021 | |
| 2021-01-06 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $267 | 2021 | |
| 2020-10-13 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $1,100 | M14-239 | 2020 |
| 2020-10-13 | ABBVIE INC. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $11,200 | M14-239 | 2020 |
| 2020-06-23 | Chiesi USA, Inc. | HAWAI I PACIFIC HEALTH | $6,500 | CUSA-081-HEM-01 | 2020 |
| 2019-10-17 | Genentech, Inc. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $1,500 | PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | 2019 |
| 2019-06-03 | Genentech, Inc. | HAWAII PACIFIC HEALTH RESEARCH INSTITUTE | $3,636 | PH III OPEN LABEL STDY ATEZO VS PLATINUM PEMETREXED GEMCITABINE FOR PDL1 CHEMO NAIVE STG IV NSCLC | 2019 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Gilroy, CA, county Santa Clara County, CA, state California; placed by its city name.
| Measure | Place (city or town) Gilroy, CA | County Santa Clara County, CA | State California |
|---|---|---|---|
| Population B01003 | 59,004 | 1,902,047 | 39,287,377 |
| Population, 2020 census P1 | 59,520 | 1,936,259 | 39,538,223 |
| Median age B01002 | 37.0 | 38.1 | 37.9 |
| Under 18 B01001 | 26.8% | 20.5% | 22.0% |
| 65 and over B01001 | 13.0% | 14.8% | 15.7% |
| Households B11001 | 17,459 | 659,353 | 13,548,091 |
| Foreign born B05002 | 24.3% | 41.5% | 27.0% |
| Median household income B19013 | $133,107 | $164,281 | $99,122 |
| Median family income B19113 | $142,150 | $187,890 | $113,346 |
| Per capita income B19301 | $48,965 | $80,312 | $49,513 |
| Poverty rate B17001 | 6.7% | 7.1% | 12.0% |
| Unemployment rate B23025 | 6.3% | 4.9% | 6.6% |
| Civilian labor force B23025 | 30,269 | 1,050,468 | 20,068,466 |
| Mean commute (minutes) B08013 | 33.3 | 26.2 | 28.7 |
| Bachelor's degree or higher B15003 | 29.3% | 56.5% | 37.1% |
| Housing units B25001 | 18,054 | 698,837 | 14,644,735 |
| Owner-occupied B25003 | 62.4% | 55.1% | 55.9% |
| Renters B25003 | 37.6% | 44.9% | 44.1% |
| Median home value B25077 | $1,027,400 | $1,490,600 | $734,700 |
| Median gross rent B25064 | $2,301 | $2,857 | $2,036 |
| White, not Hispanic B03002 | 24.3% | 27.2% | 33.8% |
| Black B03002 | 1.8% | 2.2% | 5.2% |
| Hispanic or Latino B03002 | 58.9% | 25.0% | 40.2% |
| Asian B03002 | 9.3% | 40.3% | 15.3% |
| American Indian and Alaska Native B03002 | 0.0% | 0.2% | 0.3% |
Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); the state; Source: FRED, Federal Reserve Bank of St. Louis.
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Gilroy, CA.
Comments